HCC

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

Sorafenib is small molecule inhibitor approved for the treatment of primary kidney cancer and advanced primary liver cancer.

Hepatitis C virus (HCV) has been referred to as a “stealth virus” because most people who develop chronic hepatitis C don’t know they are infected.

The medical community welcomed two new direct-acting antiviral (DAA) agents for HCV—telaprevir (Incivek, Vertex Pharmaceuticals Incorporated) and boceprevir (Victrelis, Merck & Co., Inc.)—with an excitement that hadn’t been seen since 1990.

It’s always hard to know how many new therapies will make it all the way through a drug development pipeline.There are 12 combination therapies in phase II trials, 19 individual agents in phase II, and five more in phase III.